Mymetics Starts Research Collaboration Project in Cancer Immunotherapy with eTheRNA
Epalinges, Switzerland, October 16, 2018 – Mymetics Corporation (OTCQB:MYMX), a pioneer and
leader in the research and development of virosome-based vaccines, announced today that Mymetics
BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project
with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer
immunotherapies.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Press release | Download |